Evidence map›Paper›PMID 36676020›Full record

ArticleLife (Basel, Switzerland)2022

COOBoostR: An Extreme Gradient Boosting-Based Tool for Robust Tissue or Cell-of-Origin Prediction of Tumors.

Sungmin Yang, Kyungsik Ha, Woojeung Song, Masashi Fujita, Kirsten Kübler, Paz Polak, Eiso Hiyama, Hidewaki Nakagawa, Hong-Gee Kim, Hwajin Lee

Abstract read
In one paragraph

Article in Life (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Predicting clinical outcome ofMicrobial genomics · 2025
    Article
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Sungmin YangBiomedical Knowledge Engineering Laboratory, Seoul National University, Seoul 08826, Republic of Korea.ORCID 0000-0003-0367-0424
Kyungsik HaDental Research Institute, Seoul National University, Seoul 08826, Republic of Korea.
Woojeung SongDepartment of Medicine, Hanyang University, Seoul 04763, Republic of Korea.
Masashi FujitaLaboratory of Cancer Genomics, RIKEN Center for Integrated Medical Sciences, Yokohama 230-0045, Japan.
Kirsten KüblerBerlin Institute of Health at Charité-Universitätsmedizin Berlin, Charitéplatz 1, 10117 Berlin, Germany.
Paz PolakDepartment of Oncological Sciences, Icahn School of Medicine at Mount Sinai, 1425 Madison Ave., New York, NY 10029, USA.
Eiso HiyamaNatural Science Center for Basic Research and Development, Hiroshima University, Hiroshima 739-8529, Japan.ORCID 0000-0001-9179-5037
Hidewaki NakagawaLaboratory of Cancer Genomics, RIKEN Center for Integrated Medical Sciences, Yokohama 230-0045, Japan.ORCID 0000-0003-1807-772X
Hong-Gee KimBiomedical Knowledge Engineering Laboratory, Seoul National University, Seoul 08826, Republic of Korea.
Hwajin LeeBiomedical Knowledge Engineering Laboratory, Seoul National University, Seoul 08826, Republic of Korea.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We present here COOBoostR, a computational method designed for the putative prediction of the tissue- or cell-of-origin of various cancer types. COOBoostR leverages regional somatic mutation density information and chromatin mark features to be applied to an extreme gradient boosting-based machine-learning algorithm. COOBoostR ranks chromatin marks from various tissue and cell types, which best explain the somatic mutation density landscape of any sample of interest. A specific tissue or cell type matching the chromatin mark feature with highest explanatory power is designated as a potential tissue- or cell-of-origin. Through integrating either ChIP-seq based chromatin data, along with regional somatic mutation density data derived from normal cells/tissue, precancerous lesions, and cancer types, we show that COOBoostR outperforms existing random forest-based methods in prediction speed, with comparable or better tissue or cell-of-origin prediction performance (prediction accuracy-normal cells/tissue: 76.99%, precancerous lesions: 95.65%, cancer cells: 89.39%). In addition, our results suggest a dynamic somatic mutation accumulation at the normal tissue or cell stage which could be intertwined with the changes in open chromatin marks and enhancer sites. These results further represent chromatin marks shaping the somatic mutation landscape at the early stage of mutation accumulation, possibly even before the initiation of precancerous lesions or neoplasia.

Indexed as

biocomputational methodbioinformatics-based prediction of cell-of-originepigenomicsgenomicsmachine learning

Identifiers

PMID36676020
PMCPMC9865194

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.